Stockman Wealth Management Inc. cut its position in shares of AstraZeneca plc (NYSE:AZN) by 87.3% in the first quarter, HoldingsChannel reports. The firm owned 14,342 shares of the company’s stock after selling 98,790 shares during the period. Stockman Wealth Management Inc.’s holdings in AstraZeneca were worth $580,000 as of its most recent SEC filing.
A number of other hedge funds and other institutional investors have also recently modified their holdings of AZN. Thornburg Investment Management Inc. increased its holdings in shares of AstraZeneca by 8.1% in the 1st quarter. Thornburg Investment Management Inc. now owns 707,062 shares of the company’s stock valued at $28,587,000 after acquiring an additional 52,782 shares during the period. Alethea Capital Management LLC purchased a new position in shares of AstraZeneca in the 1st quarter valued at $973,000. Heritage Wealth Advisors increased its holdings in shares of AstraZeneca by 3,378.1% in the 1st quarter. Heritage Wealth Advisors now owns 1,113 shares of the company’s stock valued at $45,000 after acquiring an additional 1,081 shares during the period. Moors & Cabot Inc. increased its holdings in shares of AstraZeneca by 11.3% in the 1st quarter. Moors & Cabot Inc. now owns 12,080 shares of the company’s stock valued at $488,000 after acquiring an additional 1,229 shares during the period. Finally, Cidel Asset Management Inc. increased its holdings in shares of AstraZeneca by 5.6% in the 1st quarter. Cidel Asset Management Inc. now owns 744,591 shares of the company’s stock valued at $30,104,000 after acquiring an additional 39,760 shares during the period. 18.32% of the stock is owned by institutional investors and hedge funds.
AstraZeneca stock traded down $0.03 during trading hours on Friday, hitting $37.77. 45,240 shares of the stock traded hands, compared to its average volume of 5,211,315. The company has a debt-to-equity ratio of 1.48, a quick ratio of 0.58 and a current ratio of 0.75. The company has a market cap of $95.44 billion, a PE ratio of 10.90, a PEG ratio of 1.16 and a beta of 0.47. AstraZeneca plc has a 1 year low of $34.38 and a 1 year high of $43.29.
AstraZeneca (NYSE:AZN) last posted its quarterly earnings results on Friday, April 26th. The company reported $0.45 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.43 by $0.02. The business had revenue of $5.47 billion for the quarter, compared to the consensus estimate of $5.40 billion. AstraZeneca had a return on equity of 37.91% and a net margin of 10.75%. The company’s quarterly revenue was up 9.6% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.48 EPS. As a group, analysts predict that AstraZeneca plc will post 1.79 EPS for the current fiscal year.
AZN has been the topic of several research analyst reports. Zacks Investment Research downgraded AstraZeneca from a “hold” rating to a “sell” rating in a research note on Tuesday, January 29th. BNP Paribas initiated coverage on AstraZeneca in a research note on Tuesday, February 5th. They set an “outperform” rating on the stock. Exane BNP Paribas initiated coverage on AstraZeneca in a research note on Tuesday, February 5th. They set an “outperform” rating on the stock. ValuEngine upgraded AstraZeneca from a “hold” rating to a “buy” rating in a research note on Thursday, February 14th. Finally, Goldman Sachs Group restated a “sell” rating on shares of AstraZeneca in a research note on Tuesday, February 26th. Three investment analysts have rated the stock with a sell rating, five have given a hold rating and twelve have given a buy rating to the company. The company has a consensus rating of “Hold” and a consensus target price of $45.29.
ILLEGAL ACTIVITY NOTICE: “AstraZeneca plc (AZN) Shares Sold by Stockman Wealth Management Inc.” was posted by The Lincolnian Online and is owned by of The Lincolnian Online. If you are viewing this report on another website, it was illegally copied and republished in violation of US and international copyright & trademark laws. The original version of this report can be accessed at https://www.thelincolnianonline.com/2019/05/17/astrazeneca-plc-azn-shares-sold-by-stockman-wealth-management-inc.html.
AstraZeneca PLC discovers, develops, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, autoimmunity, infection, neuroscience, and gastroenterology worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor, Plendil, Seloken/Toprol-XL, Tenormin, and Zestril for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.
Recommended Story: What is the cash asset ratio?
Want to see what other hedge funds are holding AZN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AstraZeneca plc (NYSE:AZN).
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.